RohamTZamanianMD

Pulmonology • Stanford, CA

Critical Care Medicine, Pleural Disease

Assistant Professor, Medicine - Pulmonary & Critical Care Medicine, Stanford University Medical Center

Join to view full profile

Dr. Zamanian is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Zamanian's full profile

Already have an account?

Office
300 Pasteur Dr
Stanford, CA 94305
Phone+1 650-723-4000

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Pulmonary Disease and Critical Care Medicine, 2002 - 2005
University of California (Irvine)Residency, Internal Medicine, 1999 - 2002
University of California, Irvine, School of MedicineClass of 1999

Certifications & Licensure

CA State Medical License 2001 - 2025

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Insulin Resistance in Pulmonary Arterial Hypertension Start of enrollment: 2008 Sep 01
Terminated
Phase 2
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) Start of enrollment: 2011 Jun 24
Completed
Phase 2
A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil). Start of enrollment: 2010 Jul 01
Completed
Phase 4
FK506 (Tacrolimus) in Pulmonary Arterial Hypertension Start of enrollment: 2012 Jul 01
Completed
Phase 2
Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument Start of enrollment: 2013 Apr 01
Completed
Phase 3
Beraprost-314d Added-on to Tyvaso® (BEAT) Start of enrollment: 2013 May 31
Completed
Phase 3
Subcutaneous Elafin in Healthy Subjects Start of enrollment: 2019 Mar 18
Completed
Phase 1
Investigation of H01 in Adults With Pulmonary Hypertension Including Interstitial Lung Disease (The SATURN Study). Start of enrollment: 2022 Apr 01
Completed
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

2 citations
Association of Phosphodiesterase-5 Inhibitor Treatment With Improved Survival in Pulmonary Hypertension Associated With COPD in the Pulmonary Vascular Research Institu...
Khodr Tello, Athiththan Yogeswaran, Raphael W Majeed, David G Kiely, Allan Lawrie
Chest. 2025-01-01
APOLLO Summary on Pulmonary Vascular Disease Fellowship Training.
Kristina Kudelko, Yon K Sung, Corey E Ventetuolo, Steven Kawut, Jeremy A Mazurek
Chest. 2024-12-20
1 citations
Novel Reference Equations for Pulmonary Artery Size and Pulsatility Using Echocardiography and Their Diagnostic Value in Pulmonary Hypertension.
Shadi P Bagherzadeh, Bettia E Celestin, Everton J Santana, Michael Salerno, Kari C Nadeau
Chest. 2024-11-01

Authored Content

Pulmonary Vascular Fellowship Training to Promote Excellence in PH Clinical Care: The Stanford PerspectiveSeptember 2020

Press Mentions

Tiakis Biotech AG Receives Positive Scientific Advice from the U.S. FDA for Planned Phase II Trial of TiprelestatJanuary 8th, 2025
Hemodynamic Trajectories and Outcomes in Patients with Pulmonary Arterial HypertensionDecember 6th, 2020
Inhaled Nitric Oxide Explored for COVID-19 OxygenationMay 13th, 2020
Join now to see all

Professional Memberships

American Thoracic Society - ATS
Member